Skip to main content

Rhabdomyolysis and/or Creatine Kinase Laboratory Results Following New Use of Statins or Angiotensin-Converting Enzyme Inhibitors

    Basic Details
    Date Posted
    Thursday, March 1, 2018
    Medical Product
    angiotensin-converting enzyme (ACE) inhibitor
    Health Outcome(s)
    creatine kinase laboratory result

    These reports contain the estimated rates of inpatient rhabdomyolysis and/or creatine kinase (CK) laboratory results following new use of statins or angiotensin-converting enzyme (ACE) inhibitors. Data from January 1, 2006 to December 31, 2015 from 11 Data Partners contributing to the Sentinel Distributed Database (SDD) were included in this report. This request was distributed on February 19, 2016.

    Additional Details
    FDA Center
    Time Period
    January 1, 2006 - December 31, 2015
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    Individuals 22 years of age and older
    Data Sources
    Sentinel Distributed Database (SDD)